Browsing: HCP Access Only

The 2026 ACC/AHA guideline introduces the 2023 PREVENT equations to replace the traditional ASCVD calculator from 2013. Here is how the new model incorporates cardiorenal-metabolic risk, social determinants, and longer-term predictions.

Dermatologist Dr Andrew Pink shares practical clinical insights on managing patients receiving nemolizumab for atopic dermatitis, including treatment expectations, adverse event monitoring, and counselling strategies in routine practice.

Dermatologist Dr Andrew Pink discusses the clinical profile of nemolizumab in atopic dermatitis, including its rapid effect on itch, improvements in sleep, and practical considerations when selecting therapy for patients with severe pruritus.

In this expert interview series, dermatologist Dr Andrew Pink explores the biological drivers of itch in atopic dermatitis and explains why addressing itch can significantly improve patients’ daily functioning and quality of life.

Want to learn about the latest advances in obesity management? In this exclusive dialogue, two renowned experts: Prof. David E. Cummings, Endocrinologist and Professor of Medicine at the
University of Washington, internationally recognised for his pioneering research on the hormonal and metabolic mechanisms regulating appetite, body weight and glucose homeostasis and Dr.
Tham Kwang Wei, Senior Consultant Endocrinologist and Chairperson of the Singapore Association for the Study of Obesity (SASO), address current unmet needs in obesity
management. Bridging the gap between medical and surgical approaches, they explored how the Dual Incretin Receptor Agonist – Tirzepatide, is redefining patient care and transforming
obesity treatment management landscape.

Atopic dermatitis itch disrupts sleep and daily life. New clinical trials reveal how nemolizumab targets the body’s main itch signal for rapid, sustained relief.